DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Triglide is a drug marketed by Skyepharma Ag and is included in one NDA. There is one patent protecting this drug.
This drug has forty patent family members in thirteen countries.
The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
A generic version of TRIGLIDE was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.
Recent Clinical Trials for TRIGLIDE
Identify potential brand extensions & 505(b)(2) entrants
|Medical University of South Carolina||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Skyepharma Ag||TRIGLIDE||fenofibrate||TABLET;ORAL||021350-001||May 7, 2005||DISCN||No||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Skyepharma Ag||TRIGLIDE||fenofibrate||TABLET;ORAL||021350-002||May 7, 2005||BX||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|